Pharmaceutical sponsor
Vigonvita Life Sciences Clinical Trials
Studies where Vigonvita Life Sciences is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 12Alzheimer Disease
A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
This study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease
- Trial name
- NCT07905352
- Testing
- Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Vigonvita Life Sciences
Healthy Participants
Study of the Safety, Tolerability, Pharmacokinetics of VV147 Tablets in Chinese Healthy Participants.
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose study designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of VV147 tablets in healthy participants.
- Trial name
- NCT07885202
- Testing
- VV147 15mg Group, VV147 30mg Group, VV147 60mg Group
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
MDD
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and…
- Trial name
- NCT06828887
- Testing
- LV232 40mg, LV232 60mg, Escitalopram
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Vigonvita Life Sciences
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Premature Ejaculation
Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE
This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.
- Trial name
- NCT07722780
- Testing
- VV913 2mg Capsules, VV913 5mg Capsules, VV913 10mg Capsules
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Healthy Volunteers
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets
This is a randomized, double-blind, placebo-controlled, multiple ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.
- Trial name
- NCT07710326
- Testing
- VV261 600mg TID group, VV261 900mg TID group
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Schizophrenia
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed…
- Trial name
- NCT07703956
- Testing
- VV119 2mg, VV119 4mg, VV119 6mg
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Healthy Volunteers
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules
This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics （PK） of multiple doses of VV913 in Chinese healthy adult participants.
- Trial name
- NCT07507838
- Testing
- VV913 4mg group, VV913 8mg group, VV913 15mg group
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Healthy Volunteers
Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers
This study is a single-center, randomized, open label, 3×3 crossover design to assess the high-fat meal and the standard meal effects on PK of a single oral dose of VV913 in healthy adult volunteers.
- Trial name
- NCT07565792
- Testing
- VV913
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Healthy Volunteers
Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants
This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV913 Capsules in healthy adults.
- Trial name
- NCT07372703
- Testing
- VV913 1mg group, VV913 2mg group, VV913 4mg group
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences